ENL by is a Other medication manufactured, distributed, or labeled by Jaymac Pharma, Viva Pharmaceuticals INC. Drug facts, warnings, and ingredients follow.
ENLTM is a medical food for use under medical supervision to assist MTHFr patients in the clinical dietary managemetnn of depression and is specially formulated to meet the distinctive nutritional requirement for these patients.
Each ENLTM capsule contains 15 mg DFE of reduced folates from DeltaFolateTM plus adenosylcobalamin.
A recent study+ suggested that EnLyte® was effective in lowering homocystine levels in patients that are positive for MTHFR (methylenetetrahydrofolate reductase polymorphism).
+ClinicalTrials.gov identifier: NCT02709668, Correlation of Clinical Response With Homocysteine Reduction During Therapy With Reduced B Vitamins in Patients with MDD Who Are Posititive for MTHFR C677T or A1298C Polymorphism.
OTHER INGREDIENTS: Annatto [colorant], 500 mcg betaine (trimethylglycine), at least 5.5 mg citrates (at least 1.83 mg citric acid, at least 3.67 mg sodium citrates), 25 mcg flavin adenine dinucleotide (reduced vitamin B2), cysteinated ferrous chelate (1.5 mg elemental iron), gelatin (bovine), glycerine, 1 mg magnesium l-threonate, 25 mcg nicotinamide adenine dinucleotide hydride (reduced vitamin B3), piperine, plant lipids (sunflower), purified water, 25 mcg pyridoxal 5’ phosphate (reduced vitamin B6), 25 mcg thiamine pyrophosphate (reduced vitamin B1), ubidecarenone, yellow beeswax. [Coenzyme B12 is the primary form most found in mammalian liver. 2Vitamer of B12 cofactor, l-methylfolate. 3Pure amino acid, cysteinated iron chelate. 4 30% daily value (DV) of VITAMIN C, and 10% DV IRON for geriatrics. 5 Contains at least 12 mg phosphatidylserine (PS)– of which approximately 6.4 mg as PS-DHA-Ca, and less than 1% EPA (<800 mcg PS-EPA-Ca).]
CONTAINS FISH/KRILL/SOY. No artificial colorants. No dairy, wheat, sugar or egg.
0.1 mg or more of vitamin B9 daily may obscure pernicious anemia in that the hematological remission may occur while neurological manifestations remain progressive. Exclusive use of vitamin B9 in treating vitamin B12-deficient macrocytic anemia could result in progressive and irreversible neurological damage. Specifically, vitamin B12 deficiency allowed to progress over 3 months may produce permanent degenerative lesions of the spinal cord - as observed when vitamin B9 therapy is used as the only hematopoietic agent. Doses of vitamin B12 exceeding 10 mcg daily may produce hematologic response in patients with vitamin B9 deficiency. Indiscriminate administration may mask the true diagnosis. A dietary deficiency of only vitamin B12 is rare; multiple vitamin deficiency is expected in any dietary deficiency. No single regimen fits all cases, and the status of the patient observed in follow-up is the final criterion for adequacy of therapy.
ENL
leucovorin, levomefolate magnesium, ferrous cysteine glycinate, 1,2-docosahexanoyl-sn-glycero-3-phosphoserine calcium, 1,2-icosapentoyl-sn-glycero-3-phosphoserine calcium, phosphatidyl serine, pyridoxal 5-phosphate, flavin adenine dinucleotide, nadh, cobamamide, cocarboxylase (thiamine pyrophosphate), magnesium ascorbate, zinc ascorbate, magnesium l-threonate and betaine capsule, liquid filled |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Labeler - Jaymac Pharma (830767260) |
Registrant - Jaymac Pharma (830767260) |
Establishment | |||
Name | Address | ID/FEI | Business Operations |
---|---|---|---|
Viva Pharmaceuticals INC | 253288898 | manufacture |